Compare iShares MSCI Indonesia ETF (EIDO) vs GE HealthCare Technologies Inc. Common Stock (GEHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs GE HealthCare Technologies Inc. Common Stock — how do they compare? iShares MSCI Indonesia ETF trades at $11.83 (market cap $398.15M), while GE HealthCare Technologies Inc. Common Stock trades at $69 (market cap $30.93B). The key difference: GE HealthCare Technologies Inc. Common Stock is far larger — about 77.7× iShares MSCI Indonesia ETF's market cap, and GE HealthCare Technologies Inc. Common Stock pays a 0.23% dividend while iShares MSCI Indonesia ETF pays none. Which is the better fit depends on your goals.
| EIDO | GEHC | |
|---|---|---|
Market Cap | $398.15M | $30.93B |
Volume | 3,087,911 | 5,033,451 |
52-Week High | $19.22 | $88.16 |
52-Week Low | $10.80 | $59.48 |
Typical Hold Time | 76 Days | — |
Sector | — | Health |
Enterprise Value | — | $39.39B |
Dividend Yield | — | 0.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EIDO (iShares MSCI Indonesia ETF) trades at $11.71, up 0.34% with bearish technical signals from moving averages and neutral oscillators. The ETF faces weak price action despite trading at a bargain valuation of 8.7x P/E. Recent news highlights foreign capital rotation away from Asian equities and Indonesia's limited benefit from commodity gains, with 44% financials weighting constraining growth potential.
Outlook remains cautious due to technical downtrend and sector concentration risks. The low valuation offers potential value, but persistent weak momentum and limited EPS growth of 5.9% temper upside. Key risks include dependence on financial sector performance and broader Asian market sentiment shifts.
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →
